Detalhe da pesquisa
1.
An IL-1ß-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.
Nat Immunol
; 25(5): 820-833, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600356
2.
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.
Nat Immunol
; 22(6): 769-780, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34017122
3.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
4.
Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299690
5.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
6.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37717583
7.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
8.
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica
; 106(11): 2799-2812, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34261295
9.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
10.
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.
Haematologica
; 104(11): 2265-2273, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948492
11.
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Blood
; 128(19): 2297-2306, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27647864
12.
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
Blood
; 126(17): 1996-2004, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26330243
13.
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial.
Haematologica
; 107(7): 1726-1730, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35295081
14.
Treatment of relapsed and refractory multiple myeloma.
Haematologica
; 101(4): 396-406, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27033237
15.
Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.
Haematologica
; 106(5): 1496-1499, 2020 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054135
16.
European Myeloma Network guidelines for the management of multiple myeloma-related complications.
Haematologica
; 100(10): 1254-66, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26432383
17.
Chemotherapy-induced peripheral neuropathies in hematological malignancies.
J Neurooncol
; 121(2): 229-37, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25326770
18.
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.
Haematologica
; 103(8): e368-e371, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545338
19.
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results.
EJHaem
; 4(4): 1117-1131, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38024633
20.
Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study.
Patient
; 16(3): 255-264, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36790557